Skip to main content
Premium Trial:

Request an Annual Quote

Start-up Illumigen Biosciences Develops New Genome Analysis Platform

NEW YORK, Feb 1 – Illumigen Biosciences, a start-up applied genomics company in Seattle, Wash., has unveiled a new computing platform for analyzing the human genome, the company said Thursday.

The system, GeneLamp, compares experimental data from Illumigen’s in-house laboratories with data from “a variety” of genomics databases to search for drug targets, according to the company.

The system will be incorporated into Illumigen's in-house experiments, which identify DNA sequence and gene expression data using proprietary population access programs.

“This program aims to speed our discovery efforts by increasing the efficiency with which we can evaluate and prioritize promising new drug targets,” Charles Magness, Illumigen's chief information officer, said in a statement.

 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.